Biond Biologics is a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer and INspire, a platform that enables intracellular delivery of biologics. Its leading development programs include BND-22 (an ILT2-blocking antibody), BND-67 (a CD28 signaling modulator) and BND-35 (an ILT3 antibody). BND-22 is being developed in a strategic collaboration with Sanofi and the first patient has been dosed in the first-in-human phase 1 trial. The company expects potential milestone payments from Sanofi that it says will help advance preclinical programs to the clinic. Biond aims to translate immunoregulatory discoveries into transformational drugs and to enable delivery of protein therapeutics to intracellular targets currently considered undruggable. The company recently closed a $15 million Series C to support advancement of its pipeline and platform. Biond Biologics, founded in 2016 by the former scientific team of cCam Biotherapeutics, is focused on discovery and development of immune-based therapies. Its in-house pipeline centers on newly discovered immune-checkpoints and immune-evasion mechanisms. The lead preclinical candidate, BION-202, is a novel macrophage activator that the company intends to advance into clinical trials; BION-206 is being developed to overcome a natural immune suppression mechanism. Biond is also developing a proprietary antibody cell-internalization platform to enable intracellular targeting of biologics. The company seeks collaborations with leading pharma groups to translate its science into therapies for diseases with unmet medical need and recently closed a $17 million Series B to fund near-term development.

Total raised

$32M

Funding rounds

2

Latest round

Series C

Latest activity

Nov 2021